Equillium to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Equillium (Nasdaq: EQ), a clinical-stage biotechnology company, will present at the Jefferies Global Healthcare Conference from June 4-6, 2024, in New York. The presentation, scheduled for June 5 at 10:30 am ET, will cover the company's clinical programs, including EQ101 for alopecia areata, with data expected by the end of June 2024. The firm will also discuss its partnership with Ono Pharmaceutical and its 2024 milestones. Management will be available for one-on-one meetings. The presentation will be webcast live and available for replay for 90 days on Equillium's website.

Positive

• Equillium to present at prestigious Jefferies Global Healthcare Conference.
• Data for EQ101 treatment for alopecia areata expected by end of June 2024.
• Partnership with Ono Pharmaceutical to be highlighted.
• Management available for one-on-one meetings during the conference.
• Webcast and 90-day replay provide accessibility for investors.

Negative

• No new clinical data or financial results disclosed in the announcement.
• Potential for delays in EQ101 data release before the end of June 2024.
• Uncertain impact of conference presentation on stock performance.

LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Jefferies Global Healthcare Conference taking place at the Marriott Marquis in New York, NY, June 4 – 6, 2024.

Management will provide an overview of the company’s clinical programs – including EQ101 for the treatment for alopecia areata with data expected before the end of June 2024 – the company’s partnership with Ono Pharmaceutical, and 2024 milestones. Management will also be available for one-on-one meetings during the conference.

Conference:	Jefferies Global Healthcare Conference
Location:	Marriott Marquis, Track 8 - Gramercy, 7th Floor
Date:	Wednesday, June 5
Time:	7:30 am Pacific Time | 10:30 am Eastern Time

Webcast access will be available on the “Events & Presentations” page under the Investor Relations tab on the Company’s website at https://www.equilliumbio.com/investors/events-and-presentations/default.aspx. An archived replay of the conference will be available for 90 days.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata being conducted in Australia and New Zealand by Equillium’s Australian subsidiary as the trial sponsor. EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21; currently in pre-clinical development. The multi-cytokine platform: generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and recently completed a Phase 1b clinical study of patients with lupus/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd., for the development and commercialization of itolizumab under an option and asset purchase agreement.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; and whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529082041/en/

Investor Contact

Michael Moore

Vice President, Investor Relations & Corporate Communications

619-302-4431

ir@equilliumbio.com

Source: Equillium, Inc.

FAQ

When will Equillium present at the Jefferies Global Healthcare Conference?

Equillium will present on June 5, 2024, at 10:30 am Eastern Time.

What will Equillium discuss at the Jefferies Global Healthcare Conference?

Equillium will provide an overview of its clinical programs, including EQ101, its partnership with Ono Pharmaceutical, and 2024 milestones.

Where can I watch Equillium's presentation at the Jefferies Global Healthcare Conference?

The presentation will be webcast live on Equillium's website under the Investor Relations section, with a replay available for 90 days.

What is the significance of EQ101 for Equillium?

EQ101 is a treatment for alopecia areata, with data expected by the end of June 2024.